title: Influenza A virus entry inhibitors targeting the hemagglutinin.
abstract: Influenza A virus (IAV) has caused seasonal influenza epidemics and influenza pandemics, which resulted in serious threat to public health and socioeconomic impacts. Until now, only 5 drugs belong to two categories are used for prophylaxis and treatment of IAV infection. Hemagglutinin (HA), the envelope glycoprotein of IAV, plays a critical role in viral binding, fusion and entry. Therefore, HA is an attractive target for developing anti‑IAV drugs to block the entry step of IAV infection. Here we reviewed the recent progress in the study of conformational changes of HA during viral fusion process and the development of HA-based IAV entry inhibitors, which may provide a new choice for controlling future influenza pandemics.
authors: School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. yjjy20071030@yahoo.cn
authors: Jie
authors: J
authors: Yang
authors: Minmin
authors: M
authors: Li
authors: Xintian
authors: X
authors: Shen
authors: Shuwen
authors: S
authors: Liu
mesh_terms: D000818:Animals; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D007251:Influenza, Human / Q000188:drug therapy / Q000821:virology*; D053586:Virus Internalization / Q000187:drug effects*
chemical_list: D019267:Hemagglutinin Glycoproteins, Influenza Virus